From: Smith, Michael (CBER)
Sent: Friday, August 13, 2021 6:22 PM
To: Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>
Cc: Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura
<Laura.Gottschalk@fda.hhs.gov>; Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>; Devlin, Carmel M
<Carmel.Devlin@pfizer.com>
Subject: STN 125742.0: 3rd set of PI labeling comments

Neda,

We have the attached 3rd set of comments on the Package Insert (PI). Please email us the further revised PI (both Word tracked-changes and Word annotated) by noon Monday, August 16, 2021, and follow up with a submission to the BLA. Please note that we will have additional comments for you on the PI next week.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

Mike Smith, Ph.D. Captain, USPHS

Senior Regulatory Review Officer Food and Drug Administration Center for Biologics Evaluation & Research Office of Vaccines Research & Review Division of Vaccines and Related Products Applications Tel: 301-796-2640 michael.smith2@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.